JOURNAL ARTICLE

Bristol Tops Estimates on New Drugs Ahead of Key Trial Results.

  • Published In: Bloomberg.com, 2026. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Smith, Gerry 3 of 3

Abstract

The article focuses on Bristol Myers Squibb Co.'s first-quarter financial performance and its strategic outlook amid patent expirations. The drugmaker reported a 3% revenue increase to $11.5 billion, driven by newer treatments like Camzyos and Breyanzi, and reaffirmed its annual forecast. Bristol faces significant sales declines due to upcoming patent losses on key drugs Opdivo and Eliquis, prompting cost cuts and acquisitions, including the $14 billion purchase of Karuna Therapeutics Inc. The company awaits critical clinical trial results for Cobenfy, a schizophrenia treatment, and milvexian, aimed at stroke and atrial fibrillation, both of which could significantly impact its future revenue. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2026/04, pN.PAG
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2026
  • Accession Number:193408026
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.